This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
I would like to thank De Panfilis for his comments regarding our recent article. We were aware of the monoclonal antibody 9.3, since its initial development and report by John Hansen in 1980. We were very interested at the time of these studies in further verifying that the infiltrating cells were cytotoxic with the use of this antibody. However, the antibody was not then commercially available in the United States, and the investigators whom we contacted to obtain the antibody were unable to give it to us at that time.We were not aware of the author's recent work with S100β and welcome this information. The current availability of 9.3 and anti-S100β antibodies will allow even more precise classification of the infiltrating lymphocytes of graft-vs-host disease.